Tag: ViiV Healthcare

ViiV Healthcare partners with Japan’s Shionogi to develop longer-acting HIV drug

Editor

USA – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK) has agreed to collaborate with Shionogi on the development of ultra-long acting HIV drugs that could be administered as little as four times a year, potentially revolutionizing HIV treatment. GSK’s VIV has also developed the long-acting HIV injection Cabenuva, which combines cabotegravir with Janssen’s rilpivirine, as well as another combination therapy of dolutegravir and lamivudine, which is administered once every one or two months. Cabenuva is indicated as a complete regimen for the treatment of human…

Read More

Enhanze drug delivery technology brings ViiV Healthcare and Halozyme into a collaboration

Editor

UK – ViiV Healthcare, a global specialist HIV that is majorly owned by GlaxoSmithKline plc have announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV. The license gives ViiV exclusive use of Halozyme’s proprietary rHuPH20 technology for four, specific HIV medicine targets that will expand opportunities for development of nearly all of ViiV’s pipeline assets. Under the terms of the agreement, ViiV Healthcare will make…

Read More